Efficacy of Lenalidomide in Myelodysplastic Syndromes
Alan F. List(TE Laboratories (Ireland)), Jerome B. Zeldis(University of California, Davis)
Cited by 874
Related Papers
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k
Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial
|Blood|2006|258
<i>TP53</i> suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients
|Proceedings of the National Academy of Sciences|2013|53
A macaque clonal hematopoiesis model demonstrates expansion of TET2-disrupted clones and utility for testing interventions
|Blood|2022|38
Oxidized Mitochondrial DNA Engages TLR9 to Activate the NLRP3 Inflammasome in Myelodysplastic Syndromes
|International Journal of Molecular Sciences|2023|38